daclatasvir (daklinza) Report issue

Small molecule Approved FDA Fast Track FDA Priority Review FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Daclatasvir (BMS-790052) is a direct-acting antiviral agent against Hepatitis C Virus (HCV) used for the treatment of chronic HCV genotype 3 infection. Daclatasvir prevents RNA replication and virion assembly by binding to NS5A, a nonstructural phosphoprotein encoded by HCV. Binding to the N-terminus of the D1 domain of NS5A prevents its interaction with host cell proteins and membranes required for virion replication complex assembly.   NCATS

Chemistry

  • SMILES: COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1c2ncc([nH]2)c3ccc(cc3)c4ccc(cc4)c5cnc([nH]5)[C@@H]6CCCN6C(=O)[C@@H](NC(=O)OC)C(C)C
  • InChIKey: FKRSSPOQAMALKA-CUPIEXAXSA-N
  • Mol. Mass: 738.89
  • ALogP: 6.22
  • ChEMBL Molecules:
    daclatasvir  
    daclatasvir dihydrochloride  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: Yes
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Alternative names

bms-790052 | bms-790052-05 | daclatasivr | daclatasvir | daclatasvir (bms-790052) | daclatasvir dihydrochloride | daclatasvir hcl | daclatasvir hydrochloride | daclatsvir | daclinza | daklinza

Organizations (133)

Research & Development (133)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (22)

Approved Indications (1)


 

Hepatitis C, Chronic

Experimental Indications - Clinical Trial Phases 1-4 (22)


 

Carcinoma, Hepatocellular (Phase 3)

COVID-19 (Phase 4)

Diabetes Mellitus (Phase 1)

Drug Interactions (Phase 1)

Drug Misuse (Phase 4)

Fibrosis (Phase 4)

Healthy Volunteers (Phase 1)

Hepacivirus (Phase 3)

Hepatic Insufficiency (Phase 1)

Hepatitis B (Phase 3)

Hepatitis C (Phase 4)

Hepatitis C, Chronic (Phase 4)

Hepatitis, Chronic (Phase 2)

HIV (Phase 3)

HIV Infections (Phase 2)

Insulin Resistance (Phase 4)

Kidney Failure, Chronic (Phase 4)

Liver Diseases (Phase 1)

Liver Transplantation (Phase 4)

Metabolic Syndrome (Phase 2/Phase 3)

Renal Insufficiency (Phase 4)

Severe Acute Respiratory Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 149
  • # of Trial Organizations: 133

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue